GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report

Eva W Iepsen, Christian T Have, Simon Veedfald, Sten Madsbad, Jens J Holst, Niels Grarup, Oluf Pedersen, Ivan Brandslund, Jens-Christian Holm, Torben Hansen, Signe S Torekov

Publikation: Bidrag til tidsskriftArtikelForskningpeer review

Abstrakt

Individuals with obesity due to pathogenic heterozygous melanocortin 4 receptor (MC4R) mutations can be treated efficiently with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) liraglutide. Here, we report the effect of 16 weeks of liraglutide 3 mg/day treatment in a woman with morbid obesity and type 2 diabetes (T2D) due to homozygous pathogenic MC4R mutation. The body weight loss was 9.7 kg, similar to weight loss in heterozygous MC4R mutation carriers and common obesity. In addition, the treatment led to clinically relevant decreases in fasting glucose, triglycerides, systolic blood pressure, and normalization of glucose tolerance. We conclude that liraglutide reduces body weight and blood glucose levels in hetero- and homozygous MC4R mutation carriers. This serves as proof-of-concept that MC4Rs are not required for the body weight and glucose lowering effects of GLP-1 RAs and that liraglutide may be used as part of the treatment of obesity and T2D due to MC4R mutations.

OriginalsprogEngelsk
Sider (fra-til)100006
TidsskriftCell reports. Medicine
Vol/bind1
Udgave nummer1
DOI
StatusUdgivet - 21 apr. 2020

Fingeraftryk Udforsk hvilke forskningsemner 'GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report' indeholder.

Citationsformater